Suxibuzone
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Suxibuzone
- DrugBank Accession Number
- DB13232
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 438.473
Monoisotopic: 438.179086574 - Chemical Formula
- C24H26N2O6
- Synonyms
- suxibuzona
- Suxibuzone
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Suxibuzone may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Abciximab. Acebutolol Suxibuzone may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Suxibuzone. Acemetacin The risk or severity of adverse effects can be increased when Suxibuzone is combined with Acemetacin. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Active Moieties
Name Kind UNII CAS InChI Key Phenylbutazone prodrug GN5P7K3T8S 50-33-9 VYMDGNCVAMGZFE-UHFFFAOYSA-N
Categories
- ATC Codes
- M02AA22 — Suxibuzone
- Drug Categories
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antiinflammatory Preparations, Non-Steroids for Topical Use
- Antirheumatic Agents
- Musculo-Skeletal System
- Nephrotoxic agents
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Pyrazoles
- Pyrazolones
- Sensory System Agents
- Topical Products for Joint and Muscular Pain
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as fatty acid esters. These are carboxylic ester derivatives of a fatty acid.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- Sub Class
- Fatty acid esters
- Direct Parent
- Fatty acid esters
- Alternative Parents
- Pyrazolidinones / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Carboxylic acid hydrazides / Carboxylic acid esters / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides show 2 more
- Substituents
- Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Carboxylic acid hydrazide / Dicarboxylic acid or derivatives / Fatty acid ester show 11 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- monocarboxylic acid, pyrazolidines (CHEBI:32173)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 86TDZ5WP2B
- CAS number
- 27470-51-5
- InChI Key
- ONWXNHPOAGOMTG-UHFFFAOYSA-N
- InChI
- InChI=1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)
- IUPAC Name
- 4-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid
- SMILES
- CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0042019
- KEGG Drug
- D01289
- ChemSpider
- 5169
- ChEBI
- 32173
- ChEMBL
- CHEMBL1414320
- ZINC
- ZINC000003875039
- PharmGKB
- PA166049191
- Wikipedia
- Suxibuzone
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.033 mg/mL ALOGPS logP 2.54 ALOGPS logP 3.68 Chemaxon logS -4.1 ALOGPS pKa (Strongest Acidic) 3.67 Chemaxon pKa (Strongest Basic) -7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 104.22 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 115.08 m3·mol-1 Chemaxon Polarizability 45.51 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-00di-9102000000-05271e9cb1c69a093216 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-00di-0006900000-83867aa3917aed3c35b9 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-0019000000-0366fd6d5ab5e5f79c7a Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4r-0019000000-f6bf3f18aee3dfb61ce7 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0pi0-0019100000-9467f519a3e417ec39be Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0ufr-0293000000-e2e801c0f833e4aa862a Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-057i-5498000000-0cf01b6249d90d99c837 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 222.6469725 predictedDarkChem Lite v0.1.0 [M-H]- 206.2849133 predictedDarkChem Lite v0.1.0 [M-H]- 219.5536725 predictedDarkChem Lite v0.1.0 [M-H]- 202.97063 predictedDeepCCS 1.0 (2019) [M+H]+ 223.8942725 predictedDarkChem Lite v0.1.0 [M+H]+ 208.1537962 predictedDarkChem Lite v0.1.0 [M+H]+ 220.1246725 predictedDarkChem Lite v0.1.0 [M+H]+ 205.36618 predictedDeepCCS 1.0 (2019) [M+Na]+ 222.5003725 predictedDarkChem Lite v0.1.0 [M+Na]+ 218.9336 predictedDarkChem Lite v0.1.0 [M+Na]+ 218.1706725 predictedDarkChem Lite v0.1.0 [M+Na]+ 211.4086 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:38 / Updated at February 21, 2021 18:54